Mutations in the Heparan-Sulfate Proteoglycan Glypican 6 (GPC6) Impair Endochondral Ossification and Cause Recessive Omodysplasia  by Campos-Xavier, Ana Belinda et al.
ARTICLE
Mutations in the Heparan-Sulfate Proteoglycan
Glypican 6 (GPC6) Impair Endochondral Ossification
and Cause Recessive Omodysplasia
Ana Belinda Campos-Xavier,1 Danielle Martinet,2 John Bateman,3 Dan Belluoccio,3 Lynn Rowley,3
Tiong Yang Tan,4 Alica Baxova´,5 Karl-Henrik Gustavson,6 Zvi U. Borochowitz,7 A. Micheil Innes,8
Sheila Unger,9,11 Jacques S. Beckmann,2,10 Laure´ane Mittaz,1 Diana Ballhausen,1 Andrea Superti-Furga,11
Ravi Savarirayan,4 and Luisa Bonafe´1,*
Glypicans are a family of glycosylphosphatidylinositol (GPI)-anchored,membrane-bound heparan sulfate (HS) proteoglycans. Their bio-
logical roles are only partly understood, although it is assumed that they modulate the activity of HS-binding growth factors. The
involvement of glypicans in developmental morphogenesis and growth regulation has been highlighted by Drosophila mutants and
by a human overgrowth syndrome with multiple malformations caused by glypican 3 mutations (Simpson-Golabi-Behmel syndrome).
We now report that autosomal-recessive omodysplasia, a genetic condition characterized by short-limbed short stature, craniofacial dys-
morphism, and variable developmental delay, maps to chromosome 13 (13q31.1-q32.2) and is caused by point mutations or by larger
genomic rearrangements in glypican 6 (GPC6). All mutations cause truncation of the GPC6 protein and abolish both the HS-binding site
and the GPI-bearing membrane-associated domain, and thus loss of function is predicted. Expression studies in microdissected mouse
growth plate revealed expression ofGpc6 in proliferative chondrocytes. Thus,GPC6 seems to have a previously unsuspected role in endo-
chondral ossiﬁcation and skeletal growth, and its functional abrogation results in a short-limb phenotype.Introduction
Heparan sulfate proteoglycans (HSPGs) are involved in
various biological processes, such as growth-factor
signaling, cell adhesion, intracellular membrane traf-
ﬁcking, and tumor metastasis.1–3 Glypicans are a family of
glycosylphosphatidylinositol (GPI)-anchored cell-surface
HSPGs sharing a highly conserved three-dimensional struc-
ture.4–6 They play key roles in the regulation of growth-
factor signaling and morphogen gradients during develop-
ment.4,7,8 Mutations in dally (division abnormally delayed),
an ortholog of mammalian glypicans 3 and 5 (GPC3 [MIM
300037] and GPC5 [MIM 602446]) in Drosophila, implicate
glypicans in the control of cell fates and division.9 The only
known human disorder caused by mutations in a glypican
core protein is Simpson-Golabi-Behmel syndrome (MIM
312870), an X-linked overgrowth/malformation syndrome
caused by mutations in GPC310 and occasionally by dele-
tion of clustered GPC3 and GPC4 (MIM 300168).11
Autosomal-recessive omodysplasia (MIM 258315) is a
genetic condition characterized by proximally shortened
limbs, facial dysmorphism, and severe short stature. The
term omodysplasia derives from ‘‘omos,’’ the Greek word
for humerus, and was ﬁrst applied by Maroteaux to a series760 The American Journal of Human Genetics 84, 760–770, June 12,of patients with syndromal short stature and hypoplastic
humeri.12 An autosomal-dominant form involving only the
upper limbs was later recognized as a separate disorder13
(MIM 164745) distinct from the recessive form. To date, 22
casesof recessiveomodysplasiahavebeenreported.14Skeletal
features comprise proximal limb shortening, distal tapering
of long tubular bones, proximal radioulnar diastasis, and an-
terolateral dislocation of the radial head. Facial features
include frontal bossing, a ﬂat nasal bridge, low set ears,
a long philtrum, anteverted nostrils, and frontal capillary
hemangiomas.Variableﬁndings are cryptorchidism,hernias,
congenital heart defects, and cognitive delay.14,15 Adult
height ranges between 132 and 144 cm (7.0 to5.5 SD).15
We report that omodysplasia maps to chromosome 13
and is caused by homozygosity for null mutations in
GPC6 (MIM 604404), which encodes for the latest
described human glypican gene.16
Material and Methods
Patients and Samples
We investigated eight patients and two products of conception
from ﬁve families (Figure 1) and one additional isolated patient
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Figure 1. Pedigrees and Haplotypes on Chromosome 13 of the Five Omodysplasia Families
In squares: regions compatible with linkage in single families. In gray: common region of homozygosity in affected individuals of consan-
guineous families.reported: family 1 is of Gypsy origin17; families 218 and 319 are
Arabic-Muslim(Lebanese); family4,previously reportedbyElcioglu
et al. (cases 3 and 4)15, is Swedish; and family 5 is Arabic-Muslim.20
Consanguinity was known in families 1, 2, 3, and 5. Patient 9 is an
adopted child; neither clinical informationnor biologicalmaterials
were available from the biological parents. Rhizomelic limb short-
ening was noted at prenatal ultrasound at 24 weeks; she was
born at 38 weeks of gestational age with birth weight 3118 g
(0.41 SD), length 41 cm (4.76 SD), and head circumference
35 cm (þ0.44 SD). A heart ultrasound was normal. At age 4 years,
she was 84 cm (4.38 SD) and 16.7 kg (þ0.85 SD); she presented
gross motor delay but normal cognitive development.
All affected individuals fulﬁlled the clinical and radiological
criteria for the diagnosis of omodysplasia. Motor delay was
a feature of all patients, but mental retardation was present only
in patients 1 and 5. Additional clinical abnormalities were cryptor-
chidism (patients 2, 5, 6, 7, and 8) and congenital heart defect
(patient 2). The radiographic ﬁndings for patient 4 (whose clinical
history and description were reported in Di Luca and Mitchell19,
without radiographic images) and the clinical and radiographic
ﬁndings for patient 9 (previously undescribed) are reported in
Figure 2.The AmBlood samples were obtained from all individuals except for the
ﬁrst unaffected fetus and the deceased twin in family 2 (Figure 1).
Genomic DNA was puriﬁed from peripheral blood leukocytes
according to standard techniques. Skin biopsies were obtained
from the unaffected parents of family 2, the affected child in
family 3 (patient 4), and the unaffected father of family 4. Fibro-
blasts were cultured in Dulbecco’s modiﬁed Eagle’s medium
(GIBCO) with 10% fetal calf serum and antibiotics and incubated
at 37Cwith 5% CO2. Total RNAwas extracted from ﬁbroblasts via
the RNeasy Mini Kit (QIAGEN) and was kept at –80C.
Appropriate written informed consent was obtained from all
individuals. The study protocol was approved by the Ethical
Committee of the University of Lausanne, Switzerland as well as
by the National Helsinki committee of Israel.
Linkage Study
We performed a genome-wide linkage scan in all ﬁve families by
using microsatellite markers (Linkage Mapping Set V2.5; Applied
Biosystems) at an average distance of 10 cM.We performed amulti-
point linkage analysis with GeneHunter version 2.1_r4_beta.
Disease gene frequency was set to 0.001, under the assumptionerican Journal of Human Genetics 84, 760–770, June 12, 2009 761
of an autosomal-recessive mode of inheritance with complete
penetrance. A unique region of interest was reﬁned with ten extra
markers of Genethon and deCODE maps.
Mutation Analysis
GPC5 (MIM 602446) and GPC6 genes were both studied in
genomic DNA of affected subjects.
For PCR ampliﬁcation ofGPC6, oligonucleotide primerswere de-
signedon thebasis of theGPC6 sequence (ENSG00000183098), tar-
geting all nine exons and 30- and 50-UTR-regions. All primers were
custom synthesized by Microsynth, and their sequences are
reported in Table S1. The entire coding sequence (including
intron-exon boundaries) and UTR regions were ampliﬁed by PCR.
Amplicon sizes and fragment-speciﬁc annealing temperatures are
reported in Table S1. To verify the ampliﬁcation products, we
used a 2% agarose gel electrophoresis. The ampliﬁed fragments
werepuriﬁedwith the standardprotocolofMontagePCRm96 (Milli-
pore). Ampliﬁcation products were analyzed by direct sequencing
with theﬂuorescentdideoxy-terminatormethodaccording to stan-
dard procedures (BigDye Terminator V1.1 Cycle Sequencing Kit,
Applied Biosystems) on an automatic sequencer, ABI 3100-Avant
(Applied Biosystems).
GPC6 cDNA was ampliﬁed by RT-PCR from total RNA extracted
from ﬁbroblasts. On the basis of the GenBank sequence of GPC6
mRNA(accessionnumberNM_005708), ﬁveoverlapping fragments
of different sizes were ampliﬁed by one-step reverse-transcription
PCR (SuperScript One-Step RT-PCR with Platinum Taq, Invitrogen)
according to the manufacturer’s instructions. The cDNA-speciﬁc
primers (Microsynth), the length of the amplicons, and the anneal-
Figure 2. Clinical and Radiographic Features of Omodysplasia
(A and B) Radiographic features of female patient 4, age 16
months. Note shortened femora and humeri with mild tapering
and distally flared metaphyses; the tibiae are also short but are
less affected. Note also the radioulnar diastasis and relative pres-
ervation of the acral skeletal elements.
(C–E) Radiographic features of female patient 9, age 5 years. Note
markedly short, ‘‘club shaped’’ humeri; shortened femora; radioul-
nar diastasis; and relative acral preservation.
(F and G) Clinical features of patient 9 at birth (F) and age 1 year
(G). Note posteriorly rotated ears, mild micrognathia, persistent
capillary hemangioma, and marked rhizomesomelic limb short-
ening.762 The American Journal of Human Genetics 84, 760–770, June 12ing temperature for each PCR are reported in Table S2. The cDNA
amplicons were migrated on 3% agarose gel NuSieve GTG Agarose,
(BioConcept);when singlebandswere obtained, PCRproductswere
directly puriﬁed according to the standard protocol of Montage
PCRm96 (Millipore); when double bands were visible on gel, each
band was excised and puriﬁed according to the standard protocol
of S.N.A.P. Gel Puriﬁcation Kit (Invitrogen). Primers used for
sequencingwere the same as for ampliﬁcation. To prevent potential
degradation of transcripts containing premature termination
codons (PTCs) by nonsense-mediated mRNA decay (NMD),21 we
treated ﬁbroblast cells (80%–90% conﬂuent) from the parents of
family 2, patient 4, the father of family 4, and one control with
cycloheximide (CHx) (Sigma-Aldrich). We treated cultured cells by
incubating cells that were 80%–90% conﬂuent in a 75 cm2 ﬂask
with 100 mg/mlCHx for 6 hr prior to theRNA extraction. After incu-
bation, cells were washed with 5 ml phosphate-buffered saline, the
ﬂask was placed on ice, and cells were collected via scraping. The
cells were transferred to a 15 ml new tube and centrifuged 10 min
at1500 rpmat roomtemperature.After careful removalof the super-
natant, the tube was put on ice, and RNA isolation was performed
according to standard protocols. The protocols for cDNA
sequencing were the same as those for genomic DNA.
Comparative Genomic Hybridization Array
Patients 3–9 and parents of patients 3–6 were studied by compar-
ative genomic hybridization array (aCGH) with the Agilent
Human Genome CGHMicroarray Kit 244KA. The aCGH platform
is a 60-mer oligonucleotide-based microarray that allows a
genome-wide survey and molecular proﬁling of genomic aberra-
tions with a resolution of ~20 kb. Labeling and hybridization were
performed according to the protocols provided by Agilent. In
brief, after digestion and puriﬁcation with the QIAprep Spin Mini-
prep kit (QIAGEN), the Agilent Genomic DNA Labeling Kit Plus
was used for labeling test and reference DNAs (1.3 mg) by random
priming with either Cy3-dUTP or Cy5-dUTP. After the labeling
reaction, the individually labeled test and reference samples
were concentrated with Microcon YM-30 ﬁlters (Millipore) and
then combined. After probe denaturation and pre-annealing
with Cot-1 DNA, hybridization was performed at 65C with rota-
tion for 40 hr. Four steps were done with Agilent Oligo CGH
washes: wash buffer 1 at room temperature for 5 min, wash buffer
2 at 37C for 1 min, acetonitrile rinse at room temperature for
1 min, and 30 s at room temperature in Agilent’s Stabilization
and Drying Solution. All slides were scanned on an Agilent DNA
microarray Scanner. Data were obtained with Agilent Feature
extraction software v9.1. Graphical overviews were obtained
with the CGH analytics software (v3.4.27) according to hg17
genome assembly (May 2004 release) subsequently translated to
the hg18 (March 2006). Copy-number variations were checked
in the database of genomic variants; all studied patients have
been considered as white because no speciﬁc data about copy-
number variations is available for Arabic Muslims.
Quantitative Multiplex PCR of Short
Fluorescent Fragments
In order to conﬁrm the genomic deletions and duplication de-
tected by aCGH with a different method and in all family
members, we used the previously described quantitative multiplex
PCR of short ﬂuorescent fragments (QMPSF) method.22–25 We de-
signed oligonucleotide primer pairs for ampliﬁcation of short exon
ﬂuorescent fragments corresponding to the nine GPC6 exons to, 2009
construct multiplex PCR; their sequences, as well as amplicon
sizes, are reported in Table S3. The multiplex reaction also con-
tained an internal control primer pair that ampliﬁed a short
sequence (237 bp) of the DSCR1 gene (MIM 602917). All forward
primers of each pair were also 50 labeled with 6-FAMﬂuorochrome.
Fluorescent multiplex PCR products (1.2 ml) were mixed with
18 ml of formamide and 0.3 ml of size-standard 500 LIZ (GeneScan
500 LIZ Size Standard, Applied Biosystems) and then separated on
an ABI Prism 310 Genetic Analyzer at 60C with POP4 polymer
(Applied Biosystems). Results were analyzed with Genescan 3.7
Software (Applied Biosystems) after superimposition of ﬂuorescent
proﬁles of patient and control DNA based on the size standard.
Proﬁles were then normalized to DSCR1 peak intensities. Then,
DSCR1-normalized peak levels of corresponding amplicons were
visually compared. The normal two-copy number of ampliﬁed
fragments appears as a completely superimposed peak area.
Heterozygous exon deletion is indicated by a 2-fold reduction in
the height (approximately 50%) of the corresponding peak,
whereas homozygous exon deletion appears as the absence of
a peak. Heterozygous exon duplication is represented by a one-
and-a-half (approximately 30%–50%) peak-size increase.
Sequencing of Genomic Breakpoints
Inorder to determine the exact lengthof thedeletions and todeﬁne
their breakpoints, we applied a strategy based on genomic ampliﬁ-
cation of a series of intronic fragments that contained an overlap-
ping commonprimer sequence: the sequenceof the forwardprimer
of each amplicon is complementary, in the inverted 50–30 direction,
to the sequence of the reverse primer of the previous amplicon
(Figure S1). Primerswere designed in the intronic regions delimited
by the rearranged aCGH probes and based on the sequence
ENSG00000183098 (chromosome 13: 92,677,711–93,853,948).
All nucleotide primers (Microsynth) are available upon request.
All fragments were ampliﬁed in patients and their parents, as well
as in two control individuals, by touch-down PCR in a GeneAmp
PCR System 9700 (Applied Biosystems). Cycling conditions are
available upon request. We used a 2% agarose gel electrophoresis
to verify the ampliﬁcation in patients and controls. For the dele-
tions found in families 2, 3, and 5 and patient 9, a certain number
of fragments were contained, at least partially, within the deletion
and failed to amplify from DNA of homozygous probands when
control DNA ampliﬁed correctly. We then ampliﬁed a single
amplicon containing the breakpoint by using as forward primer
the complementary sequence to the reverse primer of the last
ampliﬁed fragment (50 to the deletion) and as reverse primer the
complementary sequence to the forward primer of the next ampli-
ﬁed fragment (30 to the deletion) (Figure S1). The ﬁnal amplicons
containing the deletion breakpoints (Table S4) were puriﬁed by the
standard protocol of Montage PCRm96 (Millipore) and sequenced
with the same primers as those used for ampliﬁcation. The
sequencing reactionwas carriedout as described above for genomic
DNAanalysis. For family 4,we ampliﬁed all fragments byQMPSF in
patients and parents to detect the fragments that increased their
peak size by one-and-a-half and contained the start and end points
of the duplication (Figure S1). For technical reasons, the duplica-
tion breakpoints were not directly sequenced. Primer sequences
of the amplicons harboring the breakpoint of each rearrangement
are reported in Table S4.
Note: Identiﬁed sequencevariantsandmutationswerenamedac-
cording to the recommendations of the HumanGenome Variation
Society. Mutations were described according to the GPC6 cDNA
reference sequence NM_005708. For nucleotide numbering, the AThe Amof the ATG translation initiation site was used as position þ1. For
amino acid numbering, the initiationmethionine of GPC6 protein
was used as position 1. Numbering of the genomic sequence for
naming the breakpoints starts with nucleotide þ1 of the Ensembl
reference sequence ENSG00000183098 (corresponding to the
NCBI nucleotide 92677111 on chromosome 13).
Study of Glypican 6 Expression inMouse Growth Plate
Quantitative Reverse-Transcriptase Polymerase Chain Reaction
RNA from the proliferative, prehypertrophic, and hypertrophic
zones was extracted and ampliﬁed from femurs of 2-week-old
mice as described previously.26 RNA from each maturation zone
(100 ng) was reverse transcribed in a 20 ml reaction with random
hexamers and the Transcription High-Fidelity cDNA Synthesis Kit
(Roche).Quantitative PCRwas carried outwith theUniversal Probe
Library oligo set (Roche) and the LightCycler 480 ProbesMaster Kit
(Roche).PCRreactionswereperformed in10ml reactionsonaLight-
Cycler 480II real-time PCR instrument (Roche) with 1 ng of cDNA.
The datawerenormalized to thehousekeeping genemitochondrial
ATP synthase (Atp5b), whichwe have shown is expressed at consis-
tent levels throughout the growth plate (data not shown). All
samples were run in triplicate, and experiments were repeated on
the growth-plate cartilage zones microdissected from two mice.
Immunofluorescence
Tibiae from 2-week-old wild-type mice were harvested immedi-
ately after death and dissected and snap frozen in OCT compound
in liquid-nitrogen-cooled isopentane and stored at 80C. Serial
9 mm coronal frozen sections were collected on superfrost glass
slides and air dried for 1 hr. The sections were ﬁxed for 10 min
in 100% methanol. Immunostaining was performed in phos-
phate-buffered saline containing 1% bovine serum albumin. The
glypican 6 antibody (catalog # AF1053, R&D Systems) was used
at 15 mg/ml, and the antibody against collagen X (kindly provided
by Dr. R. Wilson) was used at a dilution of 1:1000. Collagen X was
used as amarker of hypertrophic zone chondrocytes. Primary anti-
body binding was detected with secondary antibodies conjugated
to Alexa Fluor 488 (donkey anti-goat IgG green) or 594 (donkey
anti-rabbit IgG red) (Molecular Probes, Eugene, OR), diluted
1:1000. Slides were mounted in Fluorosave reagent (Calbiochem)
and examined on an Olympus IX70 microscope.
Results
Recessive Omodysplasia Maps to Chromosome 13
The initial linkage-mapping screening revealed two regions
with a positive LOD score, one on chromosome 18
(18q12.2–q21.2, 7 cM, maximum LOD score 2.31) and the
other on chromosome 13 (13q31.1–q32.2, 15.7 cM, LOD
score 3.2). However, only the interval on chromosome 13
showed a common region of homozygosity in patients of
consanguineous parents and was thus selected for further
screening. Fine mapping with ten additional markers
conﬁrmed linkage and reduced the region to 4.5 cMﬂanked
by D13S265 (89.3 Mb) and D13S167 (93.8 Mb) with a
maximum LOD score Zmax ¼ 4.0 at theta ¼ 0, at the
D13S886 locus (Figure 1). According to the National Center
for Biotechnology Informationwebsite search, this 4.5-Mb-
long region contains 15 genes. GPC5 and GPC6 were ﬁrst
considered as possible candidate genes on the basis of theirerican Journal of Human Genetics 84, 760–770, June 12, 2009 763
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Figure 3. GPC6 Mutations Detected with Different Methods in Families 2, 3, 4, and 5 and in Patient 9
(A) aCGH results of patients 3, 4, 7, and 9 (homozygous deletions) and patient 5 (heterozygous duplication).
(B) QMPSF results for one proband and parents of families 2, 3, 4, and 5 (data of other siblings are not shown) and of patient 9. The peaks
obtained for the different exons in control DNA appear in blue, whereas peaks amplified from patients’ and parents’ DNA appear in green
(families 2, 3, and 5 and patient 9) or red (family 4). In family 2, the peak of exon 4 (E4) shows a 2-fold intensity reduction in the parents
compared to the control (heterozygous deletion), and it is absent in the proband (homozygous deletion). In family 3, the peaks corre-
sponding to exons 5 and 6 (E5 and E6) show a 2-fold intensity reduction in the parents compared to the control (heterozygous deletion)
and are absent in the proband (homozygous deletion); the peak of a control exon is not shown for space reasons. In family 4, the peak of
exon 4 (E4) shows a 2-fold intensity increase in the father and the proband (heterozygous duplication) and overlaps with the control in
the mother. In family 5, the peak corresponding to exon 3 shows a 2-fold intensity reduction in the parents compared to the control
(heterozygous deletion) and is absent in the proband (homozygous deletion). In patient 9, the peak of exon 3 (E3) is absent (homozy-
gous deletion), whereas the peak of the control exon (E7) overlaps with the control peak.
(C) Breakpoint sequencing results: in family 2, IVS3 and IVS4 are truncated by a genomic deletion encompassing exon 4; 19 bp are in-
serted in the breakpoint between the two intronic sequences. In family 3, IVS4 and IVS6 are truncated by a genomic deletion encompass-
ing exons 5 and 6; 3 bp are inserted in the breakpoint between the two intronic sequences. In family 5, IVS2 and IVS3 are truncated by
a genomic deletion encompassing exon 3; 9 bp are inserted in the breakpoint between the two intronic sequences. In patient 9, IVS2 and
IVS3 are truncated by a genomic deletion encompassing exon 3. Primers and genomic location of the amplicons shown here are reported
in Table S4. In family 4, the borders of the genomic duplication were mapped by QMPSF: fragments IVS3-A and IVS4-D are located 50 and 30
of the duplication, respectively; IVS3-B and IVS4-C present enhanced amplification, indicating that at least one primer is located within
the rearrangement (see also Table S4).
(D) cDNA sequencing results: exon 4 is missing in family 2; exons 5 and 6 are missing in family 3; exon 4 occurs twice in family 4.putative function as coreceptors for growth factors involved
in cellular growth control and differentiation during devel-
opment.
Mutations in GPC6 Cause Omodysplasia
Direct sequencing of GPC5 coding region, intron-exon
boundaries, and 50 and 30 UTR regions did not reveal any
mutation in affected individuals.764 The American Journal of Human Genetics 84, 760–770, June 12,Molecular studies on GPC6 include genomic direct
sequencing, aCGH studies, QMPSF, genomic breakpoint
analysis, and cDNA ampliﬁcation and sequencing. All
mutations found are summarized in Figures 3 and 4; the re-
arranged aCGH probes and the genomic breakpoints of
each rearrangement are reported in Table 1.
In family 1, the affected individuals (patients 1 and 2)
were homozygous for a single base deletion (c.778 delC)2009
Figure 4. Summary of GPC6 Mutations Found in the Studied Patients with Respect to the Gene and Protein Structure
(A) Genomic and protein structure of GPC6 gene. The proposed protein domains are shared by all glypicans. SP—signal peptide; CRD—
cysteine-rich domain; GAG—heparan-sulfate (HS) glycosylation site; GPI—glycophosphatidyl-inositol binding site, which anchors
glypican to the plasma membrane.
(B) Schematic representation of genomic mutations found in omodysplasia patients.in exon 4; this deletion is predicted to result in a frame-
shift starting at codon 260 and leading to a PTC
(p.Leu260PhefsX4). Parents and unaffected siblings were
heterozygous for the mutation.
In family 2, genomic PCR reactions with DNA of affected
subjects (patient 3 and two products of conception) failedThe Amto amplify exon 4, despite good ampliﬁcation of DNA from
the parents and control DNA. The rest of the genomic
sequence in the probands and the whole coding region
(including exon 4) in the parents were identical to the
reference sequence. These results, conﬁrmed in a second
PCR ampliﬁcation, suggested a possible genomic deletionTable 1. Genomic Rearrangements Causing Omodysplasia: aCGH Probes Involved in Genomic Rearrangements, Effect on GPC6
Gene, and Localization of Genomic Breakpoints
aCGH probesa
(50 to the Rearrangement)
aCGH Probea
(30 to the Rearrangement)
Patient
(Family)
Last Normally
Detected
First within
Rearrangement Rearrangement
Effect on
GPC6 Gene
Last within
Rearrangement
First Normally
Detected Genomic Breakpointb
3 (2) A_16_P19915562 A_16_P19915577 10 probes deleted
(66492 bp)
Deletion
of exon 4
A_16_P19915750 A_16_P40055309 g.770152_836646
del66495
4 (3) A_16_P40055823 A_16_P19916323 14 probes deleted
(99317 bp)
Deletion of
exons 5 and 6
A_16_P40056128 A_16_P19916617 g.1026129_1125444
del99316
5 and
6 (4)
A_16_P19915593 A_16_P19915610 4 probes duplicated
(26-27 kb)
Duplication
of exon 4
A_16_P02838707 A_16_P19915685 Between 784663
and 811908
7 and
8 (5)
A_16_P02838121 A_16_P19914778 12 probes deleted
(89632 bp)
Deletion
of exon 3
A_16_P19915025 A_16_P19915064 g.514476_604107
del89632
9 A_16_P02837882 A_16_P02837902 36 probes deleted
(257017 bp)
Deletion
of exon 3
A_16_P19915147 A_16_P19915180 g.376472_6633489
del257018
a Agilent Human Genome CGH Microarray Kit 244KA.
b Numbering of the genomic sequence for naming the breakpoints starts with nucleotide þ1 of the Ensembl reference sequence ENSG00000183098
(corresponding to the NCBI nucleotide 92677111 on chromosome 13).erican Journal of Human Genetics 84, 760–770, June 12, 2009 765
around exon 4. The aCGH study revealed a homozygous
genomic deletion in the affected living child (patient 3)
(Figure 3A) and heterozygosity for the same deletion in
the parents. The deletion was conﬁrmed by QMPSF
(Figure 3B) in all family members: the peak corresponding
to exon 4 shows a heterozygous deletion in the parents and
a homozygous deletion in affected individuals (patient 3
and two products of conception). All the otherGPC6 exons
showed a normal proﬁle (data not shown), conﬁrming that
the boundaries of the deletion in this family were within
IVS3 and IVS4. The genomic breakpoint of the deletion is
shown in Table 1. Moreover, in all subjects bearing the
mutation, an additional 19 base pairs were found at the
junction of the breakpoints (Figure 3C); this sequence
was not present in the published genomic sequence of
IVS3 and IVS4. RT-PCR ampliﬁcation from ﬁbroblast total
RNA of both heterozygous parents resulted in two pro-
ducts, one corresponding to the wild-type GPC6 sequence
(579 bp) and the other to a shorter fragment (413 bp) (Fig-
ure S2A) missing exon 4 (c.712_877 del) (Figure 3D). The
relative abundances of wild-type and mutant mRNAs in
heterozygous carriers (Figure S2A) as well as the enhance-
ment (Figure S2B) of mutant mRNA ampliﬁcation by
CHx treatment, which prevents mRNA degradation during
translation, are concordant with the mutant mRNA’s being
subject to NMD. The deleted sequence predicts an out-of-
frame translation with PTC (p.Val238MetfsX32).
In family 3, PCR reactions with genomic DNA of the
affected child (patient 4) failed to amplify exons 5 and 6
in two independent PCRs, despite good ampliﬁcation of
DNA from other family members and control DNA. The
rest of the genomic sequence in these individuals and
the whole coding region (including exons 5 and 6) in unaf-
fected family members were identical to the reference
sequence. These results, conﬁrmed in a second PCR ampli-
ﬁcation, suggested a possible genomic deletion around
exons 5 and 6. The aCGH study revealed a genomic homo-
zygous deletion in the affected child (Figure 3A) and a
heterozygous deletion in the parents. QMPSF analysis
was performed in all family members: the results showed
that parents and unaffected siblings were heterozygous
for the deletion of exons 5 and 6 and that the proband
was homozygous for the same deletion (Figure 3B). All
other GPC6 exons showed a normal proﬁle in all indivi-
duals (data not shown), conﬁrming that the boundaries
of the deletion in this family were within IVS4 and IVS6.
The genomic breakpoint of the deletion is shown in
Table 1. As for family 2, three additional base pairs not
present in the published genomic sequence were found
in all subjects at the breakpoint junction (Figure 3C). RT-
PCR ampliﬁcation from ﬁbroblast total RNA of the affected
patient resulted in onemain product (660 bp in Figure S2C)
corresponding to GPC6 cDNA sequence missing exons 5
and 6 (c.878_1152 del) (Figure 3D). Inhibition of NMD
by CHx treatment enhanced the abundance of the mutant
transcript (660 bp) relative to the control mRNA (935 bp)
(Figure S2D). The deleted sequence predicts a shift to766 The American Journal of Human Genetics 84, 760–770, June 12,an out-of-frame translation (p.Asp293GlyfsX12). RT-PCR
also revealed a second ampliﬁcation byproduct of 494 bp
(Figure S2C), the sequence of which missed exons 4, 5,
and 6. The deletion of the three exons predicts an in-frame,
but shorter (408 amino acids), translation product, which
lacks most of the cysteine-rich domain essential for the
globular conformation of the GPC6 core protein. Given
the proven presence of exon 4 in the genomic sequence
(seen by QMPSF and sequencing of the breakpoints in
both the affected patient and heterozygote parents) and
the lack of enhancement by NMD inhibition (Figure S2D),
this cDNA may derive from a less efﬁcient splicing from
exon 3 to exon 7.
In family 4, the affected individuals (patients 5 and6) and
their mother had a heterozygous single base substitution
(c.700C > T) leading to a nonsense mutation (p.Arg234X)
in exon 3. No mutation was found at the genomic level
by direct sequencing of the other exons and intron-
exon boundaries (all well ampliﬁed) in affected and
nonaffected family members. The aCGH study revealed
a genomic heterozygous duplication in the affected child-
ren (Figure 3A) and in the father. QMPSF analysis con-
ﬁrmed a heterozygous duplication of exon 4 (Figure 3B) in
the father and affected children; this duplication was not
present in the mother or unaffected child. All the other
GPC6 exons showed a normal proﬁle in all individuals
(data not shown), conﬁrming that the boundaries of the
duplication in this family were within IVS3 and IVS4.
Although the exact boundaries of the duplication were
not identiﬁed, the start and end of the duplication were
localized within the fragments, showing an increase in
signal intensity (approximately 30%–50%) (Figure 3C and
Table S1). RT-PCR from total RNA extracted fromﬁbroblasts
of the father showeda single ampliﬁcationproduct (579bp)
(Figure S2A)whose sequence corresponded to thewild-type
allele. RT-PCR performed after treatment of ﬁbroblast
with CHx allowed the identiﬁcation of a second product
(745 bp) corresponding to the mutant allele (Figure S2B).
Direct sequencing showed, as expected, full exon 4 duplica-
tion (c.712_877 dup) (Figure 3D). This duplication leads
to an out-of-frame translation product at the duplication
junction, and the new reading frame terminates with PTC
(p.Asp293GlyfsX46).
In family 5, PCR reactionswithDNAof the affected twins
(patients 7 and 8) failed to amplify exon 3 in two indepen-
dent PCRs, despite good ampliﬁcation of DNA from
other family members and control DNA, suggesting a
possible genomic deletion containing exon 3. The rest of
the genomic sequence in these individuals and the whole
coding region (including exon 3) in unaffected family
members were identical to the reference sequence. The
aCGHstudyperformed inoneof the affected twins revealed
a genomic homozygous deletion (Figure 3A). QMPSF anal-
ysis (Figure 3B) was performed in all family members, con-
ﬁrming the heterozygous deletion in the parents and one
of the unaffected siblings (II.4 in Figure 1). The other unaf-
fected sibling (II.1 in Figure 1) had a normal proﬁle for exon2009
3 and thus inherited the two wild-type alleles. All peaks
corresponding to the other exons were normal in all indi-
viduals (data not shown), conﬁrming that the boundaries
of the deletion in this family were located within IVS2
and IVS3. The genomic breakpoint of the deletion is shown
in Table 1. As for families 2 and 3, nine additional bp (not
present in the published genomic sequence) were found
in all subjects at the breakpoint junction (Figure 3C). The
deletion predicts an out-of-frame translation product
leading to PTC (p.Glu107GlyfsX46).
In patient 9, genomic PCR reactions failed to amplify
exon 3 in two independent PCRs, despite good ampliﬁca-
tion in controls, suggesting a possible deletion encompass-
ing exon 3. The aCGH study revealed a genomic homozy-
gous deletion (Figure 3A). The deletion was conﬁrmed by
QMPSF (Figure 3B). All other peaks of GPC6 exons ampli-
ﬁed normally (data not shown), conﬁrming that the
boundaries of the deletion were located within IVS2 and
IVS3. The genomic breakpoints of the deletion are shown
in Table 1, and the sequence is shown in Figure 3C. The
deletion predicts an out-of-frame translation product
(p.Glu107GlyfsX46).
Glypican 6 Expression Study in Mouse Growth Plate
To determine whether glypican 6 may have a role during
endochondral ossiﬁcation,we examined the relativemRNA
expression levels within mouse growth plates.
Quantitative RT-PCR performedwith total RNA obtained
from micro-dissected cartilage growth-plate subzones
showed that Gpc6 message was expressed most highly in
the proliferative zone and decreased dramatically in the
prehypertrophic and hypertrophic zones (Figure 5E). The
level of expression in the hypertrophic zone was decreased
by more than 50-fold in comparison to the proliferative
zone. Thiswas conﬁrmed at the protein level; immunoﬂuo-
rescence demonstrated Gpc6 expression by proliferative-
zone chondrocytes (Figure 5D). The localization of
collagen X (Col10a1) expression to the hypertrophic zone
of the growth plate (Figures 5B and 5E) was used for con-
ﬁrming the accuracy of the cartilage microdissection. The
expression patterns in the growth-plate cartilage of other
members of the glypican family were also determined
by quantitative RT-PCR (Figure S3). These glypicans are
expressed throughout the growth plate and do not show
the same pattern of differential expression during cartilage
hypertrophy.
Discussion
We report that omodysplasia is caused by recessive loss-of-
function mutations in a glypican HSPG gene, GPC6. This
ﬁnding conﬁrms the role of glypicans in growth control
during development, as suggested by the Drosophila
mutants dally and dly9,27 and by the association of Simp-
son-Golabi-Behmel syndrome with GPC3 mutations.10The AmFurthermore, our data highlight the role of GPC6 in skel-
etal limb growth.
All mutations found in the individuals affected by omo-
dysplasia predict absence of a functional protein. The rela-
tive abundance of wild-type and mutant mRNA in ﬁbro-
blasts of heterozygous carriers in families 2 and 4 was
concordant with the mutant mRNA’s being subject to
NMD. When escaping NMD and translated, all mutations
are expected to disrupt the three-dimensional protein struc-
ture andoften to abolishmultiple highly preserved cysteine
residues.28 All predicted mutant proteins would be trun-
catedand thereby loseboth theGPI and theHSbinding sites
(Figure 4), essential for the putative functions of GPC6.28,29
We show that omodysplasia can be caused by both point
Figure 5. Analysis of GPC6 Protein and mRNA in the Mouse
Growth Plate
(A) Toluidine-blue-stained section of growth-plate cartilage from
a 2-week-old mouse, showing the organization of the chondrocytes
in the proliferative (PR), pre-hypertrophic (PH), and hypertrophic
zones (HZ). Immunostaining shows localization of collagen X (B)
to the PH and HZ and a gradient of glypican 6 expression (D)
from the PR and PH zones to little or no expression in the HZ.
(C) Non-immune serum control. (E) Quantitative RT-PCR assay of
the mRNA expression levels of Gpc6 and Col10a1 in microdissected
cartilage zones from two biological replicates (#1 and #2). Gpc6
and Col10a1 expression was normalized to Atp5b mRNA by
a comparative CT method.erican Journal of Human Genetics 84, 760–770, June 12, 2009 767
mutations, leading to stop codon mutations, and/or larger
genomic rearrangements akin to genomicdisorders30; these
rearrangements do not appear to be mediated by low copy
repeats because none of these were found at the deletion/
duplication junctions or in general within the GPC6 gene.
The only other known human disorder caused by muta-
tions in a glypican gene is Simpson-Golabi-Behmel
syndrome; in this disorder, loss-of-function mutations
have been found in GPC3, and large deletions are respon-
sible for a signiﬁcant proportion of cases.10,31,32 Similarly
to GPC3 rearrangements, GPC6 mutations are found in
the entire coding region without any mutational hotspot
and include one or more exons. It is noteworthy that
genomic rearrangements are frequent in both glypican
genes, perhaps because they cover large genomic regions.
Because omodysplasia results from recessive loss-of-
function mutations in GPC6, hypomorphic or dominant
mutations in the same gene might result in other skeletal
phenotypes. Very recently, GPC5 haploinsufﬁciency has
been hypothesized as the molecular cause of upper limb
anomalies and growth retardation in 13q deletion
syndrome because of its expression in the developing limb
bud.33 GPC5 is colocalized with GPC6 on 13q31.2–q31.3,
and the two genes are clustered, similarly to GPC3 and
GPC4 on chromosome X, suggesting that these members
of the glypican family share an evolutionary relationship2
that might reﬂect a common function.16,34 However, given
that intact GPC5 does not compensate for loss of GPC6 in
omodysplasia patients and that Gpc5 expression in the
mouse growth plate is not signiﬁcant in comparison to
that of other glypicans (Figure S3), their functional relation-
ship is not supported by our data.
GPC6 is one of the six members of the GPI-linked
glypican subfamily of heparan sulfate proteoglycans
(HSPGs),16,28,29 widely expressed during vertebrate devel-
opment.29 As for other HSPGs,1 it has been proposed
that glypican genes inDrosophila share partially redundant
functions.9 GPC4 is the glypican most closely related to
GPC6, with which it is 64% identical.16,28,29 Despite strong
similarity and coexpression in the growth plate (Figure S3),
there appears to be no complementation between these
two molecules because mutations in GPC6 are sufﬁcient
to cause omodysplasia.
The skeletal phenotypewashomogeneous inourpatients
because only typical patients were selected for the study.
No genotype-phenotype correlation could be found
between mutations in speciﬁc domains and extra-skeletal
manifestations. Studies in mouse embryos showed that
GPC6 expression is highly distinctive in dental mesen-
chyme, metanephric cap mesenchyme, intestinal mesen-
chyme,andbloodvessels (dorsal aorta), suggestingaspeciﬁc
function in the development of these organs.29 However,
a dysfunction in one of these tissues would not directly
explain the extra-skeletal manifestations, such as cryptor-
chidism or congenital heart defects, that are reported in
omodysplasia. In the centralnervous system,GPC6colocal-
izeswithGPC4particularly in the ventricular zones,29 but it768 The American Journal of Human Genetics 84, 760–770, June 12is expressed at a much lower level than GPC4.35 Mental
retardation is not a constant feature of omodysplasia and
was present in only two patients of our series. The presence
of mental retardation as a potential additional effect of
consanguinity seems to be excluded because only one of
these two patients was born from consanguineous parents,
whereas the other one was one of the two affected siblings
of nonconsanguineous family 4.
Immunoﬂuorescence on cartilage of the mouse growth
plate showed that Gpc6 is expressed in the proliferative
zone (Figure 5D). Quantitative PCR of RNA isolated from
microdissected growth-plate cartilage conﬁrmed that Gpc6
is expressed more than 50 times more in the proliferative
zone than in the hypertrophic zone (Figure 5E). Although
themechanismbywhichGPC6 absence causes omodyspla-
sia is unknown, these expression data correlate with the
morphologic ﬁndings in the human omodysplasia growth
plate, where the proliferative zone appears expanded
compared to controls, as if a functional deﬁciency in these
physeal cells were ineffectively compensated by an
increased number of small chondrocytes.36 The differential
expression of Gpc6 mRNA in the mouse growth plate was
not observed with other glypicans (Figure S3), suggesting
a speciﬁc, nonredundant functional role for Gpc6 in prolif-
erative chondrocytes. Although animal models for GPC6
functional deﬁciency are lacking, the omodysplasia pheno-
type, together with the expression data reported above,
suggest thatGPC6 plays a role in endochondral ossiﬁcation
and long-bone elongation.
HSPGs are essential for regulation of Indian hedgehog
(IHH [MIM 600726]), ﬁbroblast growth factor, and bone
morphogenetic protein and for Wnt signaling, all key
players in endochondral ossiﬁcation.8 GPC6 is critical to
modulating the response of the growth plate to thyroid
hormones in mice37, and similar to the growth plates
of patients with omodysplasia36, growth plates of mice
harboring homozygous hypomorphic alleles of Ext1 (a HS-
polymerizing enzyme) showbroadeningof theproliferative
zone as a result of altered diffusion of the Ihh gradient.38
Although these data do not provide the mechanism of
action of glypicans in the growth plate, they show a
morphologic correlation between IHH signaling and omo-
dysplasia physeal abnormalities. At the cell surface, glypi-
cans promote the association of growth factors with their
receptors.34 Once cleaved by Notum and released in the
extracellular matrix, GPC6 core protein may be involved
in further modulation of signaling molecules.39 We postu-
late that the GPC6 mutations in our patients abrogate the
function of this HSPG in the growth plate and cause altered
growth-factor signaling and morphogen gradients leading
to failure of proliferative chondrocyte terminal differentia-
tion and long-bone growth retardation.
Supplemental Data
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